Pharmaceutical Technology-07-02-2017

Pharma company consolidation and outsourcing led to a de-emphasis of manufacturing and reduced investment in new technologies and facilities.

Cheaper drugs are good for consumers, but cost restrictions limit drug company incentives to modernize facilities.

Regulations and business changes have altered Big Pharma’s place in the industry.

Advancements in cell culture and protein technology have opened the door for new therapies.

Pharma’s test of continuous manufacturing is starting with oral solid-dosage forms.

FDA’s process validation guidance has evolved and the current lifecycle approach has profoundly influenced validation practice.

Pharmaceutical Technology marks 40 years of publishing.

Greater transparency and reliability of information are needed in the quality assessments of biosimilars.

The author reviews key technological expectations of EU GMP inspectors on the integrity of e-records.

Click the title above to open the Pharmaceutical Technology July 2017 issue in an interactive PDF format.